Skip to content

Replimune Group REPL Earnings yield

Earnings yield at other companies

Amgen logo
AmgenAMGN
4.1%+0.6pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5.4%-1.1pp
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-13.3%-888pp
Immunome logo
ImmunomeIMNM
-9.1%-3.9pp
CG Oncology logo
CG OncologyCGON
-3.3%-1.0pp
Erasca, Inc. logo
Erasca, Inc.ERAS
-5.5%-2.6pp

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Calculated from Replimune Group’s reported figures.

Based on trailing twelve months.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's earnings yield?
Replimune Group (REPL) reported earnings yield of -41.3% in Q4 2025.
How has Replimune Group's earnings yield changed year-over-year?
Replimune Group's earnings yield decreased by 68.6% year-over-year, from -24.5% to -41.3%.
What is the long-term trend for Replimune Group's earnings yield?
Over 4 years (2021 to 2025), Replimune Group's earnings yield has grown at a 55.4% compound annual growth rate (CAGR), from -5.7% to -32.9%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.